Stock search

Ticker or company name

REGN card

REGN price forecast

Regeneron Pharmaceuticals$952,40

P/E now is 21,0. Average over 5 years: 18,3 (range 15–22). The stock is 15% above its history.

Base · FY2030

$1 542,14+12,4% a year

The base case gives 12,4% a year, above your target of 10%.

Settings

%

No analyst consensus: assumptions come from the company's last 5 years. Change any in the table.

Assumptions by year

FY2026FY2027FY2028FY2029FY2030
Revenue growth, %
Net margin, %
Change in shares, %
Payout ratio, %
P/E low
P/E base
P/E high
Revenue$15,9 bn$17,7 bn$19,6 bn$21,8 bn$24,2 bn
Net income$5,69 bn$6,31 bn$7,01 bn$7,78 bn$8,64 bn
EPS$52,97$59,50$66,84$75,09$84,35

Changed values are highlighted. Bear and bull cases: growth ∓ 42,8%, margin ∓ 2 pp, low and high P/E.

Price at year end

  • Base
  • Bear – Bull
  • now $952,40

The dot is the base case, the line runs from bear to bull, the dashed line is today's price.

Result at the end of FY2030

Bear$101,96

Price change
−89,3%
A year
−41,9%
Fair value today
$68,85
Margin of safety
−92,8%

Base$1 542,14

Price change
+61,9%
A year
+12,4%
Fair value today
$1 041,37
Margin of safety
+9,3%

Bull$9 893,99

Price change
+938,8%
A year
+76,5%
Fair value today
$6 681,19
Margin of safety
+601,5%

What growth the price implies

For the stock to return 10% a year, revenue must grow 9,1% a year to FY2030 at a 35,7% margin and P/E 18,3.

Growth over 5 years
11%
Analyst consensus
no data
In your model
11%

Calculated from your assumptions. Not an investment recommendation.

Base · FY2030$1 542,14+12,4% a year